[Admin]

Semaglutide, tirzepatide, and retatrutide are frequently discussed together because they belong to the same broad family of incretin-based metabolic peptides, but each activates a different combination of receptors. This post lays out the receptor pharmacology side by side and summarizes what the published trial data shows for each.

One, Two, or Three Receptors

Semaglutide is a single-receptor GLP-1 agonist. It acts on GLP-1 receptors in the hypothalamus and brainstem to reduce appetite and food intake, and has secondary effects on gastric emptying, insulin secretion, and glucose homeostasis. It is FDA-approved as Ozempic (type 2 diabetes) and Wegovy (chronic weight management), and has the longest and largest published clinical evidence base of the three.

Tirzepatide is a dual agonist, activating both GIP and GLP-1 receptors, with research indicating an imbalanced binding profile that leans toward native-like GIP activity and biased GLP-1 activity. It is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (weight management).

Retatrutide adds glucagon receptor agonism on top of GLP-1 and GIP activity, making it a triple agonist. It remains investigational, with no regulatory approval as of this writing, but has a growing published phase 2 and phase 3 trial record.

What the Published Trial Data Shows

Semaglutide’s STEP 1 trial (Wilding et al., NEJM 2021) reported 14.9% mean body weight reduction at 68 weeks in adults with obesity or overweight, versus 2.4% with placebo. Tirzepatide’s SURPASS and SURMOUNT trial programs reported larger mean weight reductions than semaglutide monotherapy in their respective trial populations, which researchers have attributed to the added GIP receptor activity. Retatrutide’s phase 2 trial (Jastreboff et al., NEJM 2023) reported still larger mean reductions at its highest studied dose, and a 2025 network meta-analysis pooling trial data estimated retatrutide’s effect size as numerically greater than tirzepatide’s, alongside a higher reported rate of adverse events.

Read together, the published pattern is consistent with the receptor-count hypothesis — each added receptor target has correlated with larger reported effect sizes across separate trials — but this is an association across different trials and populations, not proof of a dose-response relationship established within a single controlled comparison.

Limitations Worth Keeping in Mind

None of these three compounds have been compared in a single trial that randomized the same population across all three arms. Trial durations differ (some tirzepatide and semaglutide trials now extend past two years; retatrutide’s longest published data is closer to one year). Adverse event profiles differ by mechanism and are not simply “more receptors, more side effects” — GI tolerability, injection site reactions, and other effects vary by compound and dose.

Related Reading

For a deeper look at two of these compounds specifically, see Retatrutide vs Tirzepatide: How Their Research Mechanisms Differ and our semaglutide vs retatrutide comparison. Background on the newest of the three is in our Retatrutide Research Overview, and the Semaglutide directory entry and Tirzepatide directory entry have additional reference material.

Questions for Discussion

Does the receptor-count pattern hold up as more retatrutide phase 3 data is published, or do you expect it to narrow? How should researchers weigh a longer safety track record (semaglutide, tirzepatide) against a larger reported effect size (retatrutide) when evaluating these compounds? What additional receptor targets, if any, do you think are worth researching next in this class?

This post summarizes publicly available research literature for educational and discussion purposes. It is not medical advice and does not recommend the use of any unapproved compound.

References

• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
• Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526. nejm.org
• Comparative Efficacy and Safety of Tirzepatide vs Retatrutide in Weight Loss: A Network Meta-Analysis of Clinical Trials. J Endocr Soc. 2025. PMC12544991
• Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. PMC11090168

[Author]

Posts